Results 111 to 120 of about 38,476 (212)

Evidence of comparative efficacy should have a formal role in European drug approvals [PDF]

, 2011
Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is ...
Cylus, Jonathan, Mossialos, Elias, Naci, Huseyin, Sorenson, Corinna   +3 more
core   +1 more source

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report

Majalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) increases the risk of having stroke as high as five fold. Anticoagulant administration such as vitamin K antagonist has been used regularly to reduce the occurence of stroke.
Alvin Nursalim, Yoga Yuniadi
doaj   +1 more source

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

Dabigatran‐induced esophagitis with full circumferential blue pigmentation [PDF]

, 2023
Tomonori Araki, Kohei Hayashi, Yuki Sonoda, Takuya Honda, Imamura Yoshifumi, Yuji Koide, Hisayuki Hamada, Kazuhiko Nakao   +7 more
openalex   +1 more source

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation [PDF]

, 2013
Ziad Hijazi, Stefan H. Hohnloser, Jonas Oldgren, Ulrika Andersson, Stuart J. Connolly, John W. Eikelboom, Michael D. Ezekowitz, Paul Reilly, Agneta Siegbahn, Salim Yusuf, Lars Wallentin   +10 more
openalex   +1 more source

Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban

, 2021
Oksana Volod, Marian A. Rollins‐Raval, Andrew Goodwin, Russell A. Higgins, Thomas Long, Wayne L. Chandler, Neil Harris, Huy P. Pham, James Isom, Karen Moser, John D. Olson, Kristi J. Smock, Amanda M. VanSandt, Geoffrey D. Wool, Dong Chen   +14 more
openalex   +1 more source

Thrombolysis in an Ischemic Stroke Patient on Dabigatran Anticoagulation: A Case Report [PDF]

, 2012
Luiz Carlos Porcello Marrone, A. Marrone
openalex   +1 more source

Vascular protease‐activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long‐term dabigatran administration – results from a diabetes animal model [PDF]

, 2019
Alina Scridon, Alina Mărginean, Adina Huţanu, Laura Chinezu, Dan Gheban, Marcel Perian, A Vântu, Doina Gherțescu, Paul Ciprian Fișcă, Răzvan Constantin Şerban, Philippe Chevalier, Dan Dobreanu   +11 more
openalex   +1 more source